Laura Prendergast
Stock Analyst at Stifel
(1.68)
# 3,412
Out of 5,090 analysts
15
Total ratings
50%
Success rate
-2.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Laura Prendergast
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Initiates: Buy | $15 | $9.64 | +55.68% | 1 | Dec 4, 2025 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $12 | $4.41 | +172.40% | 1 | Dec 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $115 → $135 | $109.50 | +23.29% | 2 | Nov 17, 2025 | |
| BDTX Black Diamond Therapeutics | Reinstates: Buy | $8 | $2.63 | +204.18% | 2 | Oct 16, 2025 | |
| RVMD Revolution Medicines | Reinstates: Buy | $85 | $78.96 | +7.66% | 3 | Oct 16, 2025 | |
| ERAS Erasca | Initiates: Buy | $4 | $3.27 | +22.32% | 2 | Oct 16, 2025 | |
| COGT Cogent Biosciences | Initiates: Hold | $16 | $38.85 | -58.82% | 1 | Oct 16, 2025 | |
| MURA Mural Oncology | Initiates: Strong Buy | $18 | $2.04 | +782.48% | 1 | Oct 4, 2024 | |
| NKTX Nkarta | Upgrades: Strong Buy | $16 | $1.82 | +779.12% | 2 | Aug 14, 2024 |
Tango Therapeutics
Dec 4, 2025
Initiates: Buy
Price Target: $15
Current: $9.64
Upside: +55.68%
Foghorn Therapeutics
Dec 4, 2025
Initiates: Buy
Price Target: $12
Current: $4.41
Upside: +172.40%
Nuvalent
Nov 17, 2025
Maintains: Buy
Price Target: $115 → $135
Current: $109.50
Upside: +23.29%
Black Diamond Therapeutics
Oct 16, 2025
Reinstates: Buy
Price Target: $8
Current: $2.63
Upside: +204.18%
Revolution Medicines
Oct 16, 2025
Reinstates: Buy
Price Target: $85
Current: $78.96
Upside: +7.66%
Erasca
Oct 16, 2025
Initiates: Buy
Price Target: $4
Current: $3.27
Upside: +22.32%
Cogent Biosciences
Oct 16, 2025
Initiates: Hold
Price Target: $16
Current: $38.85
Upside: -58.82%
Mural Oncology
Oct 4, 2024
Initiates: Strong Buy
Price Target: $18
Current: $2.04
Upside: +782.48%
Nkarta
Aug 14, 2024
Upgrades: Strong Buy
Price Target: $16
Current: $1.82
Upside: +779.12%